These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 191877)

  • 21. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.
    Haslam RJ; Rosson GM
    Mol Pharmacol; 1975 Sep; 11(5):528-44. PubMed ID: 170501
    [No Abstract]   [Full Text] [Related]  

  • 22. Platelet accumulation on collagen: drugs which inhibit arachidonic acid metabolism and affect intracellular cyclic AMP levels.
    Adams GA; Feuerstein IA
    Thromb Haemost; 1984 Aug; 52(1):45-9. PubMed ID: 6093281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
    Gresele P; Blockmans D; Deckmyn H; Vermylen J
    J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition and subsequent enhancement of platelet responsiveness by prostacyclin in the rabbit. Relationship to platelet adenosine 3',5'-cyclic monophosphate.
    Vanderwel M; Haslam RJ
    J Clin Invest; 1985 Jul; 76(1):233-40. PubMed ID: 2991338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do human platelets have opiate receptors?
    Reches A; Eldor A; Vogel Z; Salomon Y
    Nature; 1980 Nov; 288(5789):382-3. PubMed ID: 6253832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benzodiazepines inhibit human platelet activation: comparison of the mechanism of antiplatelet actions of flurazepam and diazepam.
    Romstedt K; Huzoor-Akbar
    Thromb Res; 1985 May; 38(4):361-74. PubMed ID: 2990062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of hypercholesterolaemia on the lipid composition and ability of human platelets to accumulate cyclic AMP.
    Jakubowski JA; Ardlie NG; Nestel PJ
    Prostaglandins Med; 1980 Dec; 5(6):457-67. PubMed ID: 6258183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proposed metabolic dysfunctions in diabetic microthromboses and microangiopathy.
    Waitzman MB
    Metabolism; 1979 Apr; 28(4 Suppl 1):401-6. PubMed ID: 233637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
    Haslam RJ; Davidson MM; Desjardins JV
    Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cyclic adenosine monophosphate, prostaglandin E and aggregation of blood platelets in man].
    Ardelt W
    Fortschr Med; 1977 Feb; 95(6):366-70. PubMed ID: 190100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclic AMP metabolism in cholesterol-rich platelets.
    Sinha AK; Shattil SJ; Colman RW
    J Biol Chem; 1977 May; 252(10):3310-4. PubMed ID: 193833
    [No Abstract]   [Full Text] [Related]  

  • 34. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
    Lecompte T; Joussemet M; Hainaut J
    Thromb Res; 1984 Jul; 35(1):91-7. PubMed ID: 6089368
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pharmacology of prostacyclin].
    Imai S
    Kokyu To Junkan; 1985 Jul; 33(7):845-9. PubMed ID: 2997894
    [No Abstract]   [Full Text] [Related]  

  • 36. Prostacyclin analogs: antiaggregatory potency and enhancement of cAMP levels in human platelet rich plasma.
    Dembinska-Kiec A; Rücker W; Schönhöfer PS; Gandolfi C
    Thromb Haemost; 1979 Dec; 42(4):1340-3. PubMed ID: 232318
    [No Abstract]   [Full Text] [Related]  

  • 37. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
    Harris RH; Nichols R; Schmeling JW; Ramwell PW
    Thromb Res; 1981 Sep; 23(6):521-32. PubMed ID: 6798707
    [No Abstract]   [Full Text] [Related]  

  • 38. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of pyridoxal-5-phosphate on the inhibition of platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation in human platelets.
    Zahavi M; Zahavi J; Kakkar VV
    Life Sci; 1984 Oct; 35(14):1497-503. PubMed ID: 6090838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cardiac effects of prostaglandins and their modification by the prostaglandin antagonist N-0164.
    Allan G; Levi R
    J Pharmacol Exp Ther; 1980 Jul; 214(1):45-9. PubMed ID: 6993659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.